Business & Economy · 56 views
Nuvalent shares surge 39% after UK's GSK agrees to buy the drugmaker for $10.6 billion
Britain's second-largest drugmaker GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what would be its largest acquisition in more than a decade.
Summary
Britain's second-largest drugmaker GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what would be its largest acquisition in more than a decade. The all-cash deal values Nuvalent at about $124 per share, according to a GSK filing on Tuesday, representing a 40% premium to its last closing price. Nuvalent shares were last seen trading 39% higher in U.S. premarket trading.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Business & Economy
Continue reading recent Business & Economy coverage
- Smart financial advisers are dropping ROI, NAV and QCD for plain English when talking to clientsContinue reading
- I’m a comedian whose joke was stolen by an AI creator. I blame Meta and feel powerless.Continue reading
- Earnings limit of up to £140K for first-time buyers loan schemeContinue reading
- How a 24-year-old turned advice from rich people into a $37 million businessContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow